Stifel lifts SpyGlass Pharma price target to $44 while retaining Buy rating

Stifel raised its price target for SpyGlass Pharma from $42 to $44 and continued to rate the shares Buy. The revision followed the company’s third-quarter 2026 results and a management discussion at the 2026 Stifel Healthcare Conference. Stifel said its higher probability assessment for BIM-DRS, after the start of its first-in-human study, contributed to the change.

The higher target and unchanged Buy rating provide a more bullish valuation view from Stifel. The analyst’s revised BIM-DRS probability assessment is the stated driver of the target increase.

  • 1Stifel’s price target moved to $44 from $42 while its Buy rating remained unchanged.
  • 2SpyGlass Pharma’s third-quarter 2026 results were released on November 12.
  • 3Stifel’s probability-of-success adjustment followed the start of BIM-DRS’s first-in-human study.
  • 4The target increase implies 32.1% upside from SpyGlass Pharma’s Nov 12 close of $33.32.

Sources